AUA Updates NMIBC Guidelines with Focus on Personalized Care and Bladder-Preserving Therapies
Event summary
- AUA and SUO released the 2026 amendment to the NMIBC guideline on September 3, 2026.
- The update includes 40 new recommendations, emphasizing individualized care and bladder-preserving therapies.
- Key additions include active surveillance, office-based treatment, and chemoablative therapies for low-grade disease.
- Guideline reflects a review of literature through December 2025 and involves experts in urologic oncology.
The big picture
The 2026 NMIBC guideline update reflects the rapid evolution of bladder cancer treatment, with a strategic shift toward individualized care and minimally invasive options. This aligns with broader trends in oncology toward precision medicine and patient-centered approaches, potentially expanding treatment access for the 80% of bladder cancer cases classified as non-muscle invasive.
What we're watching
- Therapeutic Adoption
- The pace at which clinicians adopt bladder-preserving therapies for low-grade NMIBC patients.
- Regulatory Impact
- How updated guidelines influence reimbursement and insurance coverage for emerging NMIBC treatments.
- Clinical Outcomes
- Whether personalized risk stratification improves long-term survival rates for NMIBC patients.
Related topics